Some specific antibodies indicate the presence of antigenic structures on DNA (DNA adducts) that can play an important role in the process of mutagenesis and/or carcinogenesis. They indicate the presence of increased genotoxic potential (hazard) prior to the formation of disease (primary prevention). The present study was focused on the serum level of benzo[a]pyrene 7,8-diol-9,10-epoxide-DNA adducts antibodies (anti-BPDE-DNA) in psoriatic patients (n = 55) dermally exposed to different levels of polycyclic aromatic hydrocarbons (PAHs). The general goal of the study was to contribute to better understanding of the value of the assumed biomarker (anti-BPDE-DNA) for evaluation of the organism's answer to genotoxic exposure to PAHs. Elevated level of exposure to PAHs resulted in the increased level of anti-BPDE-DNA. However, almost all levels of anti-BPDE-DNA ranged within the field of low values. Both variants of GT (CCT-3% and CCT-5%) induced higher expression of anti-BPDE-DNA in the group of nonsmokers. Significant relations between the level of anti-BPDE-DNA and PASI score, total duration of the therapy, or time of UVR exposure were not found. Further studies are needed to reduce interpretation uncertainty of this promising bioindicator.

Clinic of Dermal and Venereal Diseases University Hospital Hradec Kralove 50005 Hradec Kralove Czech Republic

Institute of Clinical Biochemistry and Diagnosis Charles University Prague Faculty of Medicine in Hradec Kralove 50038 Hradec Kralove Czech Republic

Institute of Clinical Immunology and Allergology Charles University Prague Faculty of Medicine in Hradec Kralove 50038 Hradec Kralove Czech Republic

Institute of Hygiene and Preventive Medicine Charles University Prague Faculty of Medicine in Hradec Kralove 50038 Hradec Kralove Czech Republic

Institute of Pathological Physiology Charles University Prague Faculty of Medicine in Hradec Kralove 50038 Hradec Kralove Czech Republic

Zobrazit více v PubMed

Pauk N, Klimesova S, Kara J, et al. The relevance of monitoring of antibodies against the polycyclic aromatic hydrocarbon (PAH) and PAH-DNA adducts in serum in relation to lung cancer and chronic obstructive pulmonary disease (COPD) Neoplasma. 2013;60:182–187. PubMed

Fiala Z, Borska L, Pastorkova A, et al. Genotoxic effect of Goeckerman regimen of psoriasis. Archives of Dermatological Research. 2006;298(5):243–251. PubMed

Roelofzen JHJ, van der Valk PGM, Godschalk R, et al. DNA adducts in skin biopsies and 1-hydroxypyrene in urine of psoriasis patients and healthy volunteers following treatment with coal tar. Toxicology Letters. 2011;213:39–44. PubMed

Käfferlein HU, Marczynski B, Mensing T, Brüning T. Albumin and hemoglobin adducts of benzo[a]pyrene in humans-analytical methods, exposure assessment, and recommendations for future directions. Critical Reviews in Toxicology. 2010;40(2):126–150. PubMed

Petruzzelli S, Celi A, Pulerà N, et al. Serum antibodies to benzo(a)pyrene diol epoxide-DNA adducts in the general population: effects of air pollution, tobacco smoking, and family history of lung diseases. Cancer Research. 1998;58(18):4122–4126. PubMed

Pavanello S, Dioni L, Hoxha M, et al. Mitochondrial DNA copy number and exposure to polycyclic aromatic hydrocarbons. Cancer Epidemiology, Biomarkers and Prevention. 2013;22:1722–1729. PubMed PMC

Galati R, Zijno A, Crebelli R, et al. Detection of antibodies to the Benzo(a)pyrene diol epoxide-DNA adducts in sera from individuals exposed to low doses of polycyclic aromatic hydrocarbons. Journal of Experimental and Clinical Cancer Research. 2001;20(3):359–364. PubMed

Balato N, Di Costanzo L, Ayala F, et al. Psoriatic disease and tuberculosis nowadays. Clinical and Developmental Immunology. 2012;2012:10 pages.747204 PubMed PMC

Gupta R, Debbaneh M, Butler D, et al. The Goeckerman regimen for the treatment of moderate to severe psoriasis. Journal of Visualized Experiments. 2013;77e50509 PubMed PMC

Orseth ML, Cropley TG. What's in a Name?: Goeckerman therapy. JAMA Dermatology. 2013;149:1409–1409. PubMed

Hendriks AG, Keijsers RR, de Jong EM, et al. Combinations of classical time-honoured topicals in plaque psoriasis: a systematic review. Journal of the European Academy of Dermatology and Venereology. 2013;27:399–410. PubMed

Zampetti A, Barone A, Antuzzi D, et al. Topical preparations for the treatment of psoriasis: results of a retrospective study over 15 years. Journal of Dermatological Treatment. 2008;19(3):134–140. PubMed

Moscaliuc ML, Heller MM, Lee E, et al. Goeckerman therapy: a very effective, yet often forgotten treatment for severe generalized psoriasis. Journal of Dermatological Treatment. 2013;24:34–37. PubMed

Borska L, Fiala Z, Andrys C, et al. Goeckerman's regimen: genotoxic, pro-apoptotic, anti-inflamatory and anti-angiogenic effect. In: Columbus F, editor. Dermatology Research: Focus on Acne, Melanoma, and Psoriasis. Vol. 11788. Hauppauge, NY, USA: Nova Science Publishers; 2010. pp. 141–165.

Peter Arnold W. Tar. Clinics in Dermatology. 1997;15(5):739–744. PubMed

Paghdal KV, Schwartz RA. Topical tar: back to the future. Journal of the American Academy of Dermatology. 2009;61(2):294–302. PubMed

Borska L, Smejkalova J, Cerna M, et al. Urinary mutagenicity and genotoxic risk in children with psoriasis after therapeutic exposure to polycyclic aromatic hydrocarbons and ultraviolet radiation. Mutation Research: Genetic Toxicology and Environmental Mutagenesis. 2010;696(2):144–147. PubMed

Cosmetic Ingredient Review Expert Panel. Final safety assessment of coal tar as used in cosmetics. International Journal of Toxicology. 2008;27:1–24. PubMed

Food and Drug Administration, HHS (FDA) seborrheic dermatitis, and psoriasis drug products containing coal tar and menthol for over-the counter human use, amendment to themonograph. Final rule. Federal Register. 2007;72:9849–9852. PubMed

Roelofzen JHJ, Aben KKH, van der Valk PGM, van Houtum JLM, van de Kerkhof PCM, Kiemeney LALM. Coal tar in dermatology. Journal of Dermatological Treatment. 2007;18(6):329–334. PubMed

de Rie MA, Goedkoop AY, Bos JD. Overview of psoriasis. Dermatologic Therapy. 2004;17(5):341–349. PubMed

Santella RM, Perera FP, Young TL, et al. Polycyclic aromatic hydrocarbon-DNA and protein adducts in coal tar treated patients and controls and their relationship to glutathione S-transferase genotype. Mutation Research: Environmental Mutagenesis and Related Subjects. 1995;334(2):117–124. PubMed

Topinka J, Milcova A, Libalova H, et al. Biomarkers of exposure to tobacco smoke and environmental pollutants in mothers and their transplacental transfer to the foetus. Part I: bulky DNA adducts. Mutation Research: Fundamental and Molecular Mechanisms of Mutagenesis. 2009;669(1-2):13–19. PubMed

Pulerà N, Petruzzelli S, Celi A, et al. Presence and persistence of serum anti-benzo[a]pyrene diolepoxide-DNA adduct antibodies in smokers: effects of smoking reduction and cessation. International Journal of Cancer. 1997;70:145–149. PubMed

Robbins CS, Dawe DE, Goncharova SI, et al. Cigarette smoke decreases pulmonary dendritic cells and impacts antiviral immune responsiveness. The American Journal of Respiratory Cell and Molecular Biology. 2004;30(2):202–211. PubMed

Metabolic Syndrome and Selective Inflammatory Markers in Psoriatic Patients

Selected Inflammatory and Metabolic Markers in Psoriatic Patients Treated with Goeckerman Therapy

Oxidative damage to nucleic acids and benzo(a)pyrene-7,8-diol-9,10-epoxide-DNA adducts and chromosomal aberration in children with psoriasis repeatedly exposed to crude coal tar ointment and UV radiation